Interpace Diagnostics (Nasdaq:IDXG) has joined the Pancreatic
Cancer Action Network (PanCAN) to raise critical funds and
awareness for pancreatic cancer through the Pittsburgh PurpleStride
Event. Employees and their families have united to create Team
Interpace with a goal of raising $5,000 to support PanCAN’s mission
to advance research, support patients and create hope.
The Pittsburgh PurpleStride Event, a 5K walk, will take place on
September 9th at the Northshore RiverFront Park. This community
event is planned by volunteers of PanCAN and will pay tribute to
loved ones who have succumbed to pancreatic cancer, as well as
honor those who are currently fighting it.
“Our employees in Pittsburgh are dedicated to providing
diagnostic insights to physicians and patients at risk for
developing pancreatic cancer,” said Jack Stover, President and CEO
of Interpace. “Our focus in helping these patients aligns well with
the objectives of PanCAN, and we are proud to participate in this
important cause,” he added.
As the leading pancreatic cancer organization, PanCAN is working
to expedite progress, improve patient outcomes and double survival
by 2020 through key initiatives like Precision PromiseSM and Know
Your Tumor®. The PanCAN has raised more than $87 million for
this cause through community events from 2008 to 2016.
This year, an estimated 53,670 Americans will be diagnosed with
pancreatic cancer, and approximately 43,090 will die from the
disease. The five-year survival rate for pancreatic cancer is just
nine percent.
The Pittsburgh PurpleStride event aims to improve patient
outcomes by raising significant funds for PanCAN this year.
To learn more about the Pancreatic Cancer Action Network or
PanCAN and how you can make a difference, visit www.pancan.org.
About PancraGEN®
PancraGEN® is a pancreatic cyst molecular test
that, by using a small sample of pancreatic cyst fluid, can aid in
pancreatic cancer risk assessment. PancraGEN® is
90% accurate, according to clinical studies, enabling effective
risk stratification of patients. Pancreatic cancer is often
difficult to diagnose in early stages and typically spreads rapidly
with signs and symptoms appearing when the cancer is significantly
advanced. Because of this, and that complete surgical removal of
the pancreas is not possible, pancreatic cancer is considered a
leading cause of cancer deaths.
About Interpace Diagnostics Group, Inc.
Interpace Diagnostics is a fully integrated commercial
company that provides clinically useful molecular diagnostic tests
and pathology services for evaluating risk of cancer by leveraging
the latest technology in personalized medicine for better patient
diagnosis and management. The Company currently has three
commercialized molecular tests; PancraGEN® for the diagnosis and
prognosis of pancreatic cancer; ThyGenX, for the diagnosis of
thyroid cancer from thyroid nodules utilizing a next generation
sequencing assay and ThyraMIR®, for the diagnosis of thyroid cancer
utilizing a proprietary gene expression assay. Interpace
Diagnostics' mission is to provide personalized medicine
through molecular diagnostics and innovation to advance patient
care based on rigorous science.
About the Pancreatic Cancer Action Network
(PanCAN) The Pancreatic Cancer Action Network (PanCAN) is
accelerating the pace of research progress for one of the world’s
deadliest cancers. With an urgent mission to improve outcomes
for pancreatic cancer patients and double survival by 2020, the
organization, founded in 1999, executes a bold and comprehensive
strategy to Wage Hope through research, patient services, advocacy
and community engagement. The organization’s visionary goals,
world-class programs and services, extensive grassroots network,
patient-focused outcomes and advisory board of scientific and
medical leaders, provide the critical backdrop to help pancreatic
cancer patients today and create transformational change for all
patients in the future.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, relating to the
Company's future financial and operating performance. The Company
has attempted to identify forward looking statements by terminology
including "believes," "estimates," "anticipates," "expects,"
"plans," "projects," "intends," "potential," "may," "could,"
"might," "will," "should," "approximately" or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are based on current
expectations, assumptions and uncertainties involving judgments
about, among other things, future economic, competitive and market
conditions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are
beyond the Company's control. These statements also involve known
and unknown risks, uncertainties and other factors that may cause
the Company's actual results to be materially different from those
expressed or implied by any forward-looking statement. Known and
unknown risks, uncertainties and other factors include, but are not
limited to, the Company's ability to adequately finance the
business, its ability to restructure its liabilities and other
obligations, the market's acceptance of its molecular diagnostic
tests, its ability to retain or secure reimbursement, its ability
to secure additional business and generate higher profit margins
through sales of its molecular diagnostic tests, in-licensing or
other means, projections of future revenues, growth, gross profit
and anticipated internal rate of return on investments and our
ability to maintain our NASDAQ listing. Additionally, all
forward-looking statements are subject to the risk factors detailed
from time to time in the Company's filings with the SEC, including
without limitation, the Annual Report on Form 10-K filed with the
SEC on March 31, 2017 and the amendment on Form 10-K/A filed on
April 28, 2017, the company’s Quarterly Report on Form 10-Q for the
quarter ended March 31, 2017 filed with the SEC on May 12, 2017,
and the company’s Registration Statement on Form S-1 (333-218140,
the “registration statement”) initially filed with the SEC on May
22, 2017 . Because of these and other risks, uncertainties and
assumptions, undue reliance should not be placed on these
forward-looking statements. In addition, these statements speak
only as of the date of this press release and, except as may be
required by law, the Company undertakes no obligation to revise or
update publicly any forward-looking statements for any reason.
Interpace Diagnostics Media Contact:
Paul Kuntz
RedChip
paul@redchip.com
412-708-4590
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Sep 2023 to Sep 2024